

MEDEIA THERAPEUTICS - COMPANY PRESENTATION 2011

Dr. Milla Koistinaho, CEO

Medeia's Business Model

WHAT?: Efficient vehicle from invention to non-clinical PoC

- Innovative new chemical entities (NCEs)
- In-house / acquired inventions, programs based on broad expertise of key persons
- Therapeutic areas include neurodegeneration and hormonal oncology

FOR WHOM?: Global pharma and biotechs

- High potential product candidates strengthen partners' pipelines
- Collaborative R&D leverages expertises of both parties

HOW?: Semi-virtual and cost effective company structure

- Inventions, R&D, IPR & financial management in-house
- Outsourcing of wet lab R&D work to qualified groups (industry and academia)

R&D Pipeline

Strong and balanced non-clinical portfolio of NCEs

- Innovative targets: first-in-class molecules
- Novel molecular structures possessing competitive advantages over marketed products

Focus in degenerative diseases of the elderly - high unmet medical needs and market potential

PLATFORM	FIELD	TARGET VALIDATION / IN-HOUSE EXPLORATORY	HIT IDENTIFICATION	HIT TO LEAD / LEAD OPTIMIZATION	PRE-CLINICAL CANDIDATE	IND	CLINICAL PHASES
small molecule	Neurodegeneration	MDA-107 (Partnered)					
small molecule	Neurodegeneration	MDA-107 Back up (Partnered)					
small molecule	Neurodegeneration	MDA-409					
small molecule	Hormonal oncology	MDA-308 Series A					
small molecule	Hormonal oncology	MDA-308 Series B					

MDA-107 PROGRAM

Background:

Novel small molecules invented by Medeia Research and Option (global) agreement with Orion Corp

Target diseases with no cure available at the moment

Purpose:

Discover and develop small molecules that prevent and stop further degeneration of CNS cells in diseases like Alzheimer's, Parkinson's or ALS

Status:

Several lead molecules exist

Optimized lead expected to reach non-clinical development status soon
Clinical development to be led by Orion

Back up molecules being optimized

MDA-409 PROGRAM

- Background:** A clinically validated target as a starting point
Medeia has discovered a novel mechanism to circumvent the lack of efficacy related to the existing molecules affecting this target
- Purpose:** Discover and develop novel disease modifying small molecules for degenerative diseases of the CNS
- Superiority to the existing neuroprotective compounds
- Status:** Hit molecules identified, several scaffolds exist
Customized HCA screening in C Elegans
In-house development
- Commercial potential:** Blockbuster potential - novel, patentable molecules with clinically validated M.o.A.

MDA-308 PROGRAM

- Background:** Prostate cancer is the 2nd leading cause of cancer related deaths in men. Available treatments are limited to radio and chemotherapy, surgery and antiandrogens with marginal benefit.
- Purpose:** Medeia has discovered several new chemical scaffolds addressing the shortcomings of existing androgen receptor (AR) antagonists
- Status:** Lead optimization phase ongoing
Non-clinical in vivo PoC during 2011
In-house development
- Commercial potential:** NCEs with competitive advantages over marketed products and compounds in late development

Medeia's Partnering Objectives

Medeia develops projects through non-clinical P.o.C. and seeks a partner for clinical development

Partner of choice

- Shared vision, complementary research team
- Open to early stage collaboration
- Capabilities and experience in clinical development and regulatory affairs
- Presence in at least one of the major market areas (N.A./ EU)

Deal structure must create value for the company

Contact us:

Dr. Milla Koistinaho, CEO

milla.koistinaho@medeiatherapeutics.com

tel. +358 44 5900 603

Microkatu 1, FI-70211 Kuopio, FINLAND

